Scientific deep-dive

Losing Fast Early: What It Predicts

Rapid responders in SURMOUNT-5, those down 15% or more at week 24, reported more gastrointestinal side effects and completed treatment at a similar rate to everyone else. The likely explanation is that fast loss and nausea reflect the same underlying response.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·2 citations

Losing weight quickly early on worries people in two ways: it might mean something is wrong, or it might mean they will stop early. A post hoc analysis of SURMOUNT-5 compared rapid responders against everyone else and found the reassuring version: more gastrointestinal side effects, and the same rate of completing treatment.[1]

What separated the groups

The analysis counted someone as a rapid responder if their weight was down 15% or more at week 24.[1] Rapid responders reported numerically more gastrointestinal and hepatobiliary adverse events than non-rapid responders, on both drugs. Safety trends were otherwise similar between the groups.[1]

The association has a simple explanation. These drugs work by slowing the stomach and suppressing appetite, and the people in whom that effect is strongest lose fastest and feel it most. Fast loss and nausea are two readings of the same underlying response rather than cause and effect.

Rapid responders reported more gastrointestinal and hepatobiliary adverse events, on both drugs, and completed treatment at a similar rate.

The finding that answers the worry

Study treatment completion was similar among rapid and non-rapid responders, for both drugs.[1] The extra side effects did not translate into people abandoning treatment.

The common assumption runs the other way: that a hard start predicts giving up. In this trial it did not. It is a trial population, with trial support and free medication, so the read-across to ordinary care is limited; discontinuation outside trials runs from 37% to 56%, covered in many people never reach the dose.

The head-to-head buried inside it

SURMOUNT-5 randomized people to tirzepatide or semaglutide, so it is a true head-to-head rather than a comparison across separate trials. In this analysis a greater proportion of tirzepatide participants reached every body-weight reduction threshold, in both responder groups.[1]

That is consistent with ordinary care, where tirzepatide has also produced more weight loss than semaglutide at one year (covered in what these drugs do outside a trial).

On average, fast early loss did go with a better final result. Rapid responders were more likely than non-rapid responders to reach the weight-loss thresholds by week 72.[1] That is a group average for loss measured at week 24, so it does not forecast where one person losing quickly at week four will end up.

What to do if you are losing fast

  • Expect the symptoms to travel with it. More gastrointestinal effects in fast responders is the pattern, not a complication.
  • It is not a reason to stop on this evidence, since completion rates were unaffected.
  • It is a reason to watch intake. Fast loss with a suppressed appetite is where inadequate eating happens, covered in eating too little.
  • Severe symptoms are still a prescriber conversation, and holding a dose longer is a normal, labeled option.

What happened to the people who did not respond early

A larger post hoc analysis, pooling 2,384 tirzepatide-treated participants from SURMOUNT-1 and SURMOUNT-2, split them by whether they had lost 5% of their weight by week 8 and followed both groups to week 72.[2]

Early responders did better, as expected. The more useful finding is the other one: the people who had not lost 5% by week 8 still achieved clinically meaningful weight reduction and improvements in cardiometabolic measures by week 72.

And tolerability was not the explanation. The pattern, severity and time course of gastrointestinal events were similar in both groups. So the non-responders were not people struggling with the drug or taking less of it.
One finding complicates using early response as a predictor at all: early responders were more likely to be female, White, and to have a lower baseline HbA1c. That means early response is entangled with who someone is, not only with how they are responding, and any rule built on it inherits that entanglement. The broader problem of who these trials enrolled is in who was actually in the trials.

Frequently Asked Questions

Not on this evidence. Rapid responders in SURMOUNT-5 reported more gastrointestinal and hepatobiliary adverse events, but completed treatment at the same rate as everyone else, on both drugs.
Because both come from the same response. These drugs slow the stomach and suppress appetite, so the people in whom that effect is strongest both lose fastest and feel it most.
On average, yes. In SURMOUNT-5, people whose weight was down 15% or more at week 24 were more likely to reach the weight-loss thresholds at week 72. That is a group pattern, not a forecast for one person, and it says little about loss in the first few weeks.
That is a prescriber's judgment. Either way, watch whether you are eating enough: fast loss with a suppressed appetite is exactly where inadequate intake happens.
A greater proportion of tirzepatide participants reached every weight-reduction threshold, in both responder groups. SURMOUNT-5 randomized people to the two drugs head to head, which makes that comparison stronger than the cross-trial ones usually quoted.

References

  1. 1.Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis The American Journal of Medicine. 2026. PMID: 41865857.
  2. 2.Kokkinos A, Thethi T, Lee CJ, et al. Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials Diabetes, Obesity and Metabolism. 2026. PMID: 42348366.

GLP-1s During Ramadan: What the Four Studies Actually Tested

Four studies exist on taking a GLP‑1 through Ramadan and all four enrolled people with type 2 diabetes. Both randomized trials compared against a sulfonylurea, a drug class whose defining hazard is low blood sugar.

7 min read

BPC-157 Dosage: What the Human Studies Actually Gave

There is no approved BPC-157 dose. The five published human studies used enemas, knee or bladder injections and IV infusions, never the subcutaneous, oral or topical routes sold. Why rat µg/kg doses and dosage charts do not convert.

9 min read

How Many Units Is Your GLP-1 Dose? It Depends on the Vial

A syringe measures volume, a dose is measured in milligrams, and the number connecting them is set by whichever pharmacy filled your vial. Full conversion tables for compounded semaglutide and tirzepatide.

8 min read

Where to Inject a GLP-1, and Why Rotation Matters

Belly, thigh-front or the back of an upper arm, and always under the skin rather than into muscle. Rotation is the part people quietly drop, and dropping it can look exactly like the drug having stopped working.

6 min read

GLP-1 Overdose: What Happens and What to Do

Most GLP-1 overdoses are dosing mistakes with compounded vials and cause severe nausea and vomiting that can last days. The guidance on the Ozempic, Wegovy, Mounjaro and Zepbound labels, FDA's dosing-error alert, and when to call Poison Help or 911.

10 min read

TB-500 Side Effects and Dosing: Whose Safety Data Are They?

TB-500's side effects in people are unknown and no dose has been tested. The safety data and doses quoted for it come from IV, gel and eye-drop trials of full thymosin beta-4. What HHS's October 2026 policy says, and why calculators can't fix it.

9 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

CoreAge Rx

Flat-priced compounded semaglutide at $79 a month, any dose

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

9.1

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

From $59/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →